Aug 06, 2024 13:15 JST

Source: Eisai

Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation

TOKYO, Aug 6, 2024 - (JCN Newswire) - Eisai Co., Ltd. reconfirmed that the regulatory status for anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (generic name:lecanemab) subcutaneous (SC) autoinjector, explained at the Financial Disclosure Meeting on August 2, 2024, is as follows.

The SC formulation (including initiation and maintenance dosing) received Fast Track designation from the

U.S. Food and Drug Administration (FDA). In agreement with the FDA, Eisai initiated a rolling submission and review for SC maintenance dosing in May 2024. In parallel, discussions are ongoing with the FDA regarding optimal dosage and the fastest regulatory pathway for the SC initiation dosing. There are no changes to the previously announced timeline for the SC application at this time. We expect to complete the rolling application for SC maintenance dosing in the third quarter of fiscal year 2024 ending March 2025, with a review period of six months if designated for priority review or ten months under standard review. For SC initiation dosing, we aim to obtain a regulatory approval by the end of fiscal year 2025 ending March 2026.

A supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing was submitted to the FDA in March 2024 and accepted in June of the same year. The PDUFA (Prescription Drugs User Fee Act) action date is set for January 25, 2025.

Eisai is committed to making the IV maintenance dosing and SC formulation available as new treatment options to people with early AD as soon as possible.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
September 05 2024 15:59 JST
 
Eisai Announces Status Relating to Acquisition of Own Shares
September 02 2024 14:12 JST
 
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22 2024 18:54 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
August 14 2024 08:59 JST
 
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
July 31 2024 12:59 JST
 
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
July 29 2024 16:59 JST
 
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
July 25 2024 09:30 JST
 
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
July 23 2024 19:23 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 12 2024 11:56 JST
 
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
July 11 2024 09:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>